confirms that novel 2-DG analogs, such as WP1122, and HDAC inhibitors (like sodium butyrate and sodium valproate) exhibit significant synergistic anticancer effects, inhibiting the proliferation of GBM cells and inducing apoptosis. This evidence concerns the gene HDAC9 and glioblastoma.